Every year on 4 February, the world observes World Cancer Day — a global initiative dedicated to raising awareness of cancer, promoting early detection, and advocating improved access to prevention and treatment strategies worldwide. Beyond cancer-specific screening aimed at early tumor detection, tumor marker tests and other relevant biomarkers are always included to provide additional clinical insights.

Wondfo Biotech is committed to providing high-quality in vitro diagnostic solutions that support early disease detection and monitoring across diverse clinical settings. Wondfo’s testing portfolio includes a wide range of biomarkers relevant to  oncological assessment. Our portfolio encompasses a broad range of assays, including immunofluorescence, chemiluminescence, and rapid tests for oncology-related conditions. Through advanced diagnostic platforms, clinicians can integrate data from multiple assays to support a holistic view of patient health, particularly for individuals with overlapping risk factors.



One of our flagship technologies is the ACCRE CLIA Platform, designed to deliver reliable accuracy, operational efficiency, flexibility, and maintenance-free performance. You can learn more about this system here:
https://en.wondfo.com/Chemiluminescence-Platform.html

This platform supports a broad menu of biomarkers commonly used in cancer-related testing. These include tumor markers such as carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), cancer antigen 125 (CA125), cancer antigen 15-3 (CA15-3), and cancer antigen 19-9 (CA19-9).
These biomarkers are widely applied in cancer risk assessment and are also used to support the monitoring of disease progression and treatment response.
 


Racing for Life, Wondfo continues to advance diagnostic technologies and expand its testing menu, contributing to the early screening of cancer and supporting timely clinical decision-making.